Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update.

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome. That's welcome news.

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.

Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...

Participants who respond to batoclimab therapy in Period 1 (responders are defined as those achieving a ≥1 point improvement from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Participants who respond to batoclimab therapy in Period 1 (responders are defined as those achieving a ≥1 point improvement from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a ...